MabSelect PrismA

Addressing
higher demands

Improved capacity allows handling of the ever-increasing upstream titers, resolving bottlenecks in downstream mAb processing. A significantly enhanced alkaline stability ensures a better process economy, while meeting the requirements of a stringent bioburden control.


Maximizing
productivity

With enhanced properties of both the agarose base matrix and the Protein A ligand, MabSelect PrismA offers significantly increased capacity compared with its predecessor resins.


Optimizing
CIP/SIP

Improved alkaline stability enables more efficient cleaning and sanitization to prevent carryover and enhance bioburden control in downstream mAb capture.


Improving
facility use

Higher binding capacity decreases the resin volume required and increases mass throughput per purification cycle using existing equipment, ultimately enabling a delayed capital investment.

MabSelect PrismA enables a more efficient use of existing manufacturing footprint.


Downloads